RELATED STUDY
Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
Key Findings: This reviewed the current knowledge base of cannabis, the endocannabinoid system, receptor sites, and addresses the growing interest and potential profitability of the commercial and academic pursuits in the cannabis industry.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Australia
Year of Pub: 2021
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabinol (CBN), Cannabichromenic Acid (CBC-a), Cannabidiolic Acid (CBD-a), Cannabigerolic Acid (CBG-a), Tetrahydrocannabinolic Acid (THC-a), Abnormal Cannabidiol (Abn-CBD), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Tetrahydrocannabivarin (THCV), Lysophosphatidylinositol (LPI), Delta-8-THC
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, TRPA1, TRPV1, TRPV2, TRPV4, TRPM8, PPAR - Alpha, PPAR - Gamma, GPCR, TRPs
Ligands Studied: Acetylcholine, Dopamine, GABA, Insulin, Serotonin, Pro-inflammatory cytokines, Glucocorticoid
